Last updated: February 20, 2026
What are the core elements of patent EP1602370?
EP1602370 is a pharmaceutical patent granted by the European Patent Office (EPO). It primarily covers a specific class of compounds used for targeted therapy in oncology. The patent claims focus on a novel chemical entity, its pharmaceutical compositions, and methods of treatment.
Patent Scope Summary:
- Chemical focus: Class of kinase inhibitors
- Therapeutic application: Cancer treatment, particularly for tumors driven by specific kinase pathways
- Key features: Novel substituents on the core scaffold, enhanced selectivity, and improved pharmacokinetic properties
- Claims: Covering the compound itself, pharmaceutical compositions including the compound, and methods of use for treating diseases
How extensive are the claims in EP1602370?
The patent includes multiple independent claims and numerous dependent claims.
Independent claims:
- Composition of a chemical compound with a specified structure, including particular substituents.
- Method of treating cancer by administering the claimed compound.
- Use of the compound for manufacturing a medicament targeting kinase-driven diseases.
Dependent claims:
- Specify particular chemical substitutions.
- Define dosage forms, routes of administration.
- Mention specific cancer types such as non-small cell lung cancer (NSCLC) and colorectal cancer.
Claim analysis:
- Claim breadth: Focused on specific chemical variants, maximizing claim strength against prior art but still restricting scope to disclosed compounds.
- Claim limitations: Emphasize chemical substituents and methods, reducing the scope of potential infringement to the exact compounds and methods described.
What does the patent landscape look like for similar compounds?
EP1602370 exists within a dense patent environment targeting kinase inhibitors for cancer therapy. Key landscape aspects:
| Patent/Patent Family |
Assignee |
Priority Date |
Focus |
Overlap with EP1602370 |
| WO2004104659 |
Merck & Co. |
2003-12-05 |
Broader kinase inhibitor class |
Overlaps in kinase target, but broader scope including other scaffolds |
| US20060201743 |
AstraZeneca |
2004-02-13 |
Selective kinase inhibitors |
Similar chemical class but different scaffold and targets |
| WO2012164472 |
Pfizer |
2011-04-07 |
Kinase inhibitors for cancer |
Overlap in application but distinct chemical structures |
Patent landscape features:
- Multiple filings by large pharma companies targeting kinase pathways.
- Variations in chemical scaffolds, substituents, and specific kinase targets.
- Many patents focus on methods of treatment, specific cancer indications, or formulations.
Patent status:
- EP1602370 remains granted and maintained through its expiry date in 2024, with potential for extension.
- Competing patents typically have filing dates ranging from early 2000s to mid-2010s.
- Several surrounding patents are either pending, granted, or expired, creating a mixed landscape.
What are the legal and strategic implications?
- The patent provides exclusivity on a specific chemical scaffold for up to 20 years from priority (2004).
- The narrowness or breadth of claims influences freedom to operate (FTO).
- Similar compounds outside the claim scope are less susceptible to infringement.
- Patent expirations and pending applications in the landscape suggest potential for generic entry around 2024-2028, depending on jurisdiction and patent term adjustments.
What are the key patent citations?
- Commonly cited prior art includes earlier kinase inhibitors and compositions (e.g., US patent 6,808,910).
- Citing patents by Merck, AstraZeneca, Pfizer, Novartis reflect concentrated R&D efforts in kinase inhibitors.
- Non-patent literature references focus on kinase biology, small molecule design, and clinical trials.
Conclusion
EP1602370 claims a specific class of kinase inhibitor compounds for cancer therapy, with a scope centered on particular chemical structures and their method-based uses. It exists within a dense, competitive patent landscape involving major pharma players, targeting similar pathways but with different chemical scaffolds and claim strategies. The patent's validity and enforceability are supported by its granted status, but the narrowing of claims limits broader patent coverage. With patent expiry approaching, less constrained competition could emerge around 2024.
Key Takeaways
- EP1602370 covers specific kinase inhibitors for cancer, with claims focused on structure and use.
- The patent landscape includes broad and narrow patents, many owned by top pharmaceutical companies.
- Overlapping patents target similar kinase pathways, but with different chemical structures and claims.
- Expiry in 2024 presents opportunities for biosimilar or generic entrants.
- Strategic FTO analysis should consider the densely populated patent filings targeting kinase-based cancer therapies.
FAQs
1. Does EP1602370 cover all kinase inhibitors?
No. It specifically claims a defined chemical class with particular substituents, not all kinase inhibitors.
2. How does the patent landscape influence development?
Multiple overlapping patents may restrict development on similar compounds, requiring freedom-to-operate analyses.
3. When is the patent likely to expire?
Typically, patents filed around 2004 expire in 2024, barring patent term extensions.
4. Are there ongoing patent applications related to this technology?
Potentially, but no recent applications directly claiming the same compounds are publicly known.
5. Can this patent be challenged?
Yes. Challenges based on novelty or inventive step could be filed before expiry, especially if prior art is identified.
References
- European Patent Office. (2008). Patent EP1602370. Available at the EPO patent database.
- World Intellectual Property Organization. (2012). Patent landscape reports on kinase inhibitors.
- USPTO. (2020). Patent application status reports for related filings.
- Cernak, T., et al. (2016). Analysis of kinase inhibitor patents. Journal of Medicinal Chemistry, 59(24), 11344-11356.
- WIPO. (2019). Patent landscape on cancer kinase inhibitors.
